Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Intangibles: 2019-2025

Historic Intangibles for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $134.9 million.

  • Pharming Group N.V's Intangibles rose 101.09% to $134.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.9 million, marking a year-over-year increase of 101.09%. This contributed to the annual value of $61.0 million for FY2024, which is 14.35% down from last year.
  • Pharming Group N.V's Intangibles amounted to $134.9 million in Q3 2025, which was down 0.72% from $135.9 million recorded in Q2 2025.
  • Pharming Group N.V's Intangibles' 5-year high stood at $138.9 million during Q1 2025, with a 5-year trough of -$1.2 million in Q2 2021.
  • Moreover, its 3-year median value for Intangibles was $71.3 million (2023), whereas its average is $87.5 million.
  • Its Intangibles has fluctuated over the past 5 years, first skyrocketed by 99,509.26% in 2023, then decreased by 14.35% in 2024.
  • Over the past 5 years, Pharming Group N.V's Intangibles (Quarterly) stood at $83.8 million in 2021, then fell by 10.39% to $75.1 million in 2022, then fell by 5.13% to $71.3 million in 2023, then declined by 14.35% to $61.0 million in 2024, then surged by 101.09% to $134.9 million in 2025.
  • Its Intangibles was $134.9 million in Q3 2025, compared to $135.9 million in Q2 2025 and $138.9 million in Q1 2025.